NCT02980536

cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China

The Oncogenic Mutation Detection of Advanced NSCLC Patients by cSMART Liquid Biopsy and Dynamic Monitor of Tyrosine Kinase Inhibitor(TKI) Efficiency in Inner-Mongolia China

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 129 (actual)
• Sponsor: Berry Genomics Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the mutation pattern of epidermal growth factor receptor (EGFR) and other TKI targeted gene during TKI treatment of advanced NSCLC patient with liquid biopsy.

Detailed description

In the study, 200 advanced NSCLC patients will be recruited. All the patients will receive biopsy genotype assay and Circulating Single-Molecule Amplification and Resequencing Technology (cSMART) liquid biopsy. those patients who carry EGFR activating mutation and other TKI targeted activating mutation will receive TKI treatment. During the TKI treatment, every patients will take liquid biopsy assay to monitor the mutation status. the study will be ended when all the patients had a progressive disease (PD) in their targeted lesion

Conditions

• Nonsmall Cell Lung Cancer
• Adenocarcinoma

Timeline

• Start date: 2016-11-01
• Primary completion: 2018-10-01
• Completion: 2018-12-01
• First posted: 2016-12-02
• Last updated: 2018-07-11

Locations

9 sites across 1 country: China